GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Medicilon Inc (SHSE:688202) » Definitions » Debt-to-Revenue

Shanghai Medicilon (SHSE:688202) Debt-to-Revenue : 0.33 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Medicilon Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Medicilon's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥324 Mil. Shanghai Medicilon's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥15 Mil. Shanghai Medicilon's annualized Revenue for the quarter that ended in Mar. 2024 was ¥1,038 Mil. Shanghai Medicilon's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.33.


Shanghai Medicilon Debt-to-Revenue Historical Data

The historical data trend for Shanghai Medicilon's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Medicilon Debt-to-Revenue Chart

Shanghai Medicilon Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.08 0.04 0.17 0.28

Shanghai Medicilon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.28 0.39 0.53 0.33

Competitive Comparison of Shanghai Medicilon's Debt-to-Revenue

For the Biotechnology subindustry, Shanghai Medicilon's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Medicilon's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Medicilon's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Medicilon's Debt-to-Revenue falls into.



Shanghai Medicilon Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Shanghai Medicilon's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(368.598 + 14.28) / 1365.631
=0.28

Shanghai Medicilon's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(324.015 + 14.718) / 1038.024
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Shanghai Medicilon Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Medicilon's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Medicilon (SHSE:688202) Business Description

Traded in Other Exchanges
N/A
Address
Lane 67, Libing Road, Building 5, Pilot Free Trade Zone, Shanghai, CHN, 201299
Shanghai Medicilon Inc is a comprehensive biomedical research and developemnt service company. It provides a full range of one-stop new drug development services for pharmaceutical companies and research institutions around the world in line with domestic and international reporting standards.

Shanghai Medicilon (SHSE:688202) Headlines

No Headlines